medigraphic.com
ISSN 1561-3186 (Digital)

2009, Número 1

<< Anterior Siguiente >>

Rev Acta Médica 2009; 12 (1)


Manejo práctico de la hiperglucemia en la diabetes mellitus tipo 2

Buchaca FEF, Rodríguez AL

Idioma: Español
Referencias bibliográficas: 47
Paginas:
Archivo PDF: 228.19 Kb.


RESUMEN

En este tema de revisión se exponen los principales criterios diagnósticos de los trastornos del metabolismo de los carbohidratos, desde el estado de prediabetes. Se insiste en las medidas de automonitoreo de la glucemia como herramienta que contribuye al tratamiento de acuerdo con las metas, y se muestran las equivalencias de los promedios de glucemia con la hemoglobina glucosilada. Se incluye una breve actualización de los distintos grupos de drogas con efecto antihiperglucemiante, con breves anotaciones sobre su mecanismo principal de acción, indicaciones y efectos adversos. Un aspecto a resaltar es la recomendación de tratamiento combinado de drogas orales con la insulina. Finalmente, se sugiere un algoritmo de decisiones terapéuticas de acuerdo con los niveles de glucemia y hemoglobina glucosilada, según recomendaciones de grupos de expertos, reforzando el uso oportuno de la insulina en personas con diabetes tipo 2 y el enfoque individualizado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. International Diabetes Federation. Diabetes Atlas. http://www.eatlas.idf.org(accessed 12 October 2008. Disponible en:)

  2. Díaz Díaz O. La epidemiología de la diabetes en Cuba. Disponible en: http://www.sld.cu/galerias/pdf/sitios/diabetes/epidemiologia_de_la_diabetes_en_c uba.pdf

  3. American Diabetes Association. Standars of Medical Care-2009. Diabetes Care. 2009; 32(Suppl 1):S13-61.

  4. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Eng J Med. 1993; 329:978-86.

  5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.

  6. American Diabetes Association: Standards of medical care in diabetes-2008 (Position Statement). Diabetes Care. 2008; 31(Suppl.1):S12-S54.

  7. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31:1473-78.

  8. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000; 342:381-9.

  9. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006; 29:340-4.

  10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89.

  11. Nathan D. Finding new treatment for diabetes-How many, how fast…how good?N Eng J Med. 2007; 356:437-40.

  12. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baronl MA. PRESERVE-beta: two year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005; 28:2093-9.

  13. Rachman J, Payne M, Levy J, Barrow B, Holman R, Turner R: Changes in amylin and amylin-peptide concentrations and function in response to sulfonylurea or insulin therapy in type 2 diabetes. Diabetes Care. 1998; 21:810-6.

  14. Maedler K, Carr R, Bosco D, Zuellig R, Berney T, Donath M: Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005; 90:501-6.

  15. Lebovitz HE. In: Joslin's Diabetes Mellitus. 1994. p. 508-29.

  16. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-43.

  17. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999; 22(1):119-24.

  18. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000; 23(11):1660-65.

  19. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus: A Multicenter Controlled Clinical Trial. Ann Intern Med. 1994; 121:928-35.

  20. DeFronzo RA, Goodman M. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. N Engl J Med. 1995; 333:541-9.

  21. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65.

  22. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298:1189-95.

  23. Hollander P, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobelet SA, et al. Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes, A 1-year randomized controlled trial. Diabetes Care. 2003; 26(3):784-90.

  24. Nauck MA, Trautman M, Brodows R, Johns E, Northrup J, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulphonylurea and metformin: a non-inferiority study. Diabetologia. 2007; 50:259-67.

  25. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12):2632-37.

  26. Zammitt N, Frier B. Hypoglycemia in Type 2 Diabetes.Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005; 28:2948-61.

  27. Johnson JL, Wolf SL, Kabadi UM: Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996; 156:259-64.

  28. Yki-Jarvinen H: Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001; 24:758-67.

  29. Massi Benedetti M, Orsini Federici M. Treatment of Type 2 Diabetes with Combined Therapy What are the pros and cons? Diabetes Care. 2008; 31 (Suppl. 2):S131-35.

  30. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993; 16:21-31.

  31. Holman RR. Long term efficacy of sulfonylureas: A United Kingdom Prospective Study perspective. Metab Clin Exp. 2006; 55(Suppl 1):S2-S5.

  32. Turner RC.UKPDS 49. JAMA. 1999; 281:2005-12.

  33. Standl E, Schnello O. Insulin as a first-line therapy in type 2 diabetes. Should the use of sulfonylureas be halted? Diabetes Care. 2008; 31 (Suppl 2):136-9.

  34. Riddle MC. Combined therapy with insulin plus oral agents: Is there any advantage? An argument in favor. Diabetes Care. 2008; 31 (Suppl 2):S125-130.

  35. Garber AF: Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102:491-7.

  36. Goldberg RB, et al. The Glimepiride Protocol #201 Study Group: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996; 19:849-56.

  37. Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus tipo 2. Rev. Asoc. Latinoamericana Diabetes. 2006; 1-70

  38. Nathan D, Buse J, Davidson B, Heine R, Holman R, Sherwin R: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006; 29:1963-72.

  39. Shaw JS, Wilmot RL, Kilpatrick ES: Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007; 24:1160-63.

  40. Furlong NJ, Hulme SA, O'Brien SV and Hardy KJ. Repaglinide Versus Metformin in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Established on Insulin/Metformin Combination Therapy. Diabetes Care. 2002; 25:1685-90.

  41. Strowig SM, Avilés-Santa ML, Raskin P. Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes. Diabetes Care. 2002; 25:1691-8.

  42. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS: The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998; 21:701-5.

  43. Buchaca E, Fanghanel G, Sánchez L. «Tratamiento combinado de Insulina y Sulfonilureas en la falla secundaria a Hipoglucemiantes orales». Revista Asociación Latinoamericana de Diabetes. 1995, 3(2):137.

  44. Nathan D, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes. A consensus algorithm for the initiation and adjustment of therapy. A Consensus Statement of the American Diabetes Associations and European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.

  45. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007;13(Suppl 1):19.

  46. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59.

  47. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-72.




2020     |     www.medigraphic.com